Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1505

Sort by

Sort Order Select

Journal Articles

Aspirin and antiplatelet treatments in cancer

Derrick L. Tao, Samuel Tassi Yunga, Craig D. Williams, Owen J. T. McCarty

Blood (2021) 137 (23): 3201–3211.

https://doi.org/10.1182/blood.2019003977

Published: 2021

Journal Articles

Introduction to a review series on platelets and cancer

José A. López

Blood (2021) 137 (23): 3151–3152.

https://doi.org/10.1182/blood.2020010237

Published: 2021

Journal Articles

Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors

Blood (2021) 137 (15): 2103–2113.

https://doi.org/10.1182/blood.2020007488

Published: 2021

Includes: Supplemental data

Journal Articles

Platelet glycoprotein VI promotes metastasis through interaction with cancer cell–derived galectin-3

Elmina Mammadova-Bach, Jesus Gil-Pulido, Edita Sarukhanyan, Philipp Burkard, Sergey Shityakov, Charlotte Schonhart, David Stegner, Katharina Remer, Paquita Nurden, Alan T. Nurden, Thomas Dandekar, Laszlo Nehez, Magdolna Dank, Attila Braun, Diego Mezzano, Scott I. Abrams, Bernhard Nieswandt

Blood (2020) 135 (14): 1146–1160.

https://doi.org/10.1182/blood.2019002649

Published: 2020

Includes: Supplemental data

Journal Articles

Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin

Katsue Suzuki-Inoue

Blood (2019) 134 (22): 1912–1918.

https://doi.org/10.1182/blood.2019001388

Published: 2019

Journal Articles

RUNX2 Regulates Cell Migration in T-Cell Lineage Acute Lymphoblastic Leukemia

Nitesh Devinarayan Sharma, PhD, Christian C. Nickl, Huining Kang, PhD, Wojciech Ornatowski, PhD, Stuart S. Winter, MD, Mignon L. Loh, MD, Stephen P. Hunger, MD, Ksenia Matlawska-Wasowska, PhD

Blood (2019) 134 (Supplement_1): 3947.

https://doi.org/10.1182/blood-2019-129337

Published: 2019

Journal Articles

Influence of Bone Marrow Stromal and Leukemic Cells on Cytarabine Chemo-Toxicity in Acute Myeloid Leukemia (AML)

Liana E Gynn, BSc, Elizabeth Anderson, PhD, Gareth M Robinson, PhD, Sarah Anne Wexler, MBBS, MRCP, FRCPath, Gillian Upstill-Goddard, Christine Cox, Rhys Gareth Morgan, PhD, Jennifer E May, PhD BSc

Blood (2019) 134 (Supplement_1): 2492.

https://doi.org/10.1182/blood-2019-122891

Published: 2019

Journal Articles

A Unique Crosstalk between Tumor Cells and Hematopoietic Stem Cells Reveals a Myeloid Differentiation Pattern Signature Contributing to Metastasis

Ksenia Magidey, PhD, Ksenya Kveler, PhD, Rachelly Normand, PhD, Tongwu Zhang, PhD, Michael Timaner, PhD, Ziv Raviv, PhD, Brian James, PhD, Roi Gazit, PhD, Ze'ev Ronai, PhD, Shai Shen-Orr, PhD, Yuval Shaked, PhD

Blood (2019) 134 (Supplement_1): 2465.

https://doi.org/10.1182/blood-2019-128126

Published: 2019

Journal Articles

Inhibiting Matrix Metalloproteinases Hinders Acute Myeloid Leukaemia and Prevents Healthy Stem Cell Loss

Chiara Pirillo, Myriam Haltalli, Sara Gonzalez-anton, George Adams, Delfim Duarte, Cristina Lo Celso

Blood (2019) 134 (Supplement_1): 2487.

https://doi.org/10.1182/blood-2019-129847

Published: 2019

Journal Articles

Characteristics and Outcomes of Patients with Lymphoma Who Developed Therapy-Related Acute Myeloid Leukemia or Myelodysplastic Syndrome - a Retrospective Analysis of the Polish Adult Leukemia Group

Aleksandra Golos, MD PhD, Krzysztof Mądry, MD PhD, Karol Lis, Marta Sobas, MD, Agnieszka Ożańska, Magdalena Czemerska, Dorota Hawrylecka, Agnieszka Stelmach-Gołdyś, Karolina Chromik, Bartosz Pula, Ewa Lech-Maranda, MD PhD, Joanna Gora Tybor, MD PhD

Blood (2019) 134 (Supplement_1): 5422.

https://doi.org/10.1182/blood-2019-125711

Published: 2019

Journal Articles

AVM0703, a New Treatment Option for Lymphoma Patients

Theresa Deisher, PhD, Margaret Taylor, Arya Ashok, PhD, Peter Jarzyna, PhD, Yumna Zahid, Stephanie Lee-Diaz, Colleen Rylatt, Kendra Poulin, Vaishnavi Parthasarathy

Blood (2019) 134 (Supplement_1): 5308.

https://doi.org/10.1182/blood-2019-128812

Published: 2019

Journal Articles

Niveau, a Phase 3 Study for Pts with B- or T-Cell Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivo lumab in Combination with G e mcitabine, Ox a liplatin (GemOx), Plus Rit u ximab (R) in Case of B-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 5311.

https://doi.org/10.1182/blood-2019-129362

Published: 2019

Journal Articles

Leukemia Cutis As an Early Presentation or Relapsing Manifestation of Chronic Lymphocytic Leukemia

Mahmood B Aldapt, MD, Mohamed A Yassin, MBBS, MSc

Blood (2019) 134 (Supplement_1): 5461.

https://doi.org/10.1182/blood-2019-121654

Published: 2019

Journal Articles

Insulin-like Growth Factor-1-Induced Epithelial-Mesenchymal Transition Promotes Multiple Myeloma Progression

Yue Peng, Xiaman Wang, Ying Shen, MD, Fangmei Li, PhD, Ru Zhang, MD, Yachun Jia, Aili He

Blood (2019) 134 (Supplement_1): 5541.

https://doi.org/10.1182/blood-2019-127714

Published: 2019

Journal Articles

Metastatic Lymphoepithelioma-like Carcinoma Treated with PD1-Antibody:Is Epstein-Barr Virus Eradication the Main Mechanism in 2 Refractory Cases in Children?

Haixia Guo, MD PhD, Xuedong Wu, MD PhD, Na LI, Jian LI

Blood (2019) 134 (Supplement_1): 5615.

https://doi.org/10.1182/blood-2019-129871

Published: 2019

Journal Articles

ANTI-PD-1 Treatment in a Family with Constitutional Mismatch Repair Deficiency Syndrome with Multiple Cancers from Turkey. Is Cancer Immunoprevention with Checkpoint Inhibitors HAS a Role in CASES with Homozygous Mutationis

Emel Unal, Derya Ozyoruk, Nurdan Tacyildiz, Ferda Pi̇narli̇, A Erdogan, S Hanalioglu, Arzu Erdem, Meral Beksac, MD

Blood (2019) 134 (Supplement_1): 5632.

https://doi.org/10.1182/blood-2019-130102

Published: 2019

Journal Articles

Analysis of Outcomes of Younger (≤ 55 Years) Compared with Older (> 55 Years) Patients with Chronic Lymphocytic Leukaemia (CLL) in Seven Studies Conducted By the German CLL Study Group (GCLLSG)

Nisha De Silva, MBBS, MRCP, FRCPath, Sandra Robrecht, PhD, Can Zhang, PhD, Paula Cramer, Anna- Maria Fink, MD, Kirsten Fischer, MD, Valentin Goede, MD, Carmen D. Herling, MD PhD, Manuela Hoechstetter, MD, Clemens-Martin Wendtner, MD, Michael Hallek, MD, Barbara F. Eichhorst, MD

Blood (2019) 134 (Supplement_1): 4293.

https://doi.org/10.1182/blood-2019-126528

Published: 2019

Journal Articles

FBXO11 Is a Candidate Tumor Suppressor in the Transformation of MDS to Secondary AML

Michael Schieber, MD, John D. Crispino, PhD MBA

Blood (2019) 134 (Supplement_1): 4217.

https://doi.org/10.1182/blood-2019-124007

Published: 2019

Journal Articles

Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase Inhibition

Tamara K Moyo, MD PhD, Justin M. Watts, MD, Barry S. Skikne, MD, Jason H. Mendler, MD PhD, Virginia M. Klimek, MD, Sheau-Chiann Chen, PhD, Run Fan, PhD MS, Ingrid A Anderson, PhD, Andrew Sochacki, MD, Stephen A. Strickland, MD, Michael T Byrne, DO, Terrence J Bradley, MD, Gregory D Ayers, MS, Sanjay R Mohan, MD MSCI, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 4236.

https://doi.org/10.1182/blood-2019-130003

Published: 2019

Journal Articles

Oral Fludarabine and Intravenous Rituximab (FR) for Chronic Lymphocytic Leukemia (CLL): Long Term Outcomes and Secondary Malignancies in 673 Patients Treated in British Columbia (BC)

Elysha Vanderveer, MD BSc, Steven J.T. Huang, BMLSc, Helene Bruyere, MD FCCMG, Tanya Gillan, PhD FCCMG, Charles H. Li, MDFRCPC, Khaled Ramadan, MBBCH, MRCP, FRCPath, Diego Villa, MD MPH, David W. Scott, MBChB, PhD, Kerry J Savage, BSc, MD MSc, Joseph M Connors, MD, Laurie H Sehn, MD, Cynthia L Toze, MD FRCPC, Alina S Gerrie, MD MPH

Blood (2019) 134 (Supplement_1): 4300.

https://doi.org/10.1182/blood-2019-125189

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Aspirin and antiplatelet treatments in cancer

Introduction to a review series on platelets and cancer

Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors

Platelet glycoprotein VI promotes metastasis through interaction with cancer cell–derived galectin-3

Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin

RUNX2 Regulates Cell Migration in T-Cell Lineage Acute Lymphoblastic Leukemia

Influence of Bone Marrow Stromal and Leukemic Cells on Cytarabine Chemo-Toxicity in Acute Myeloid Leukemia (AML)

A Unique Crosstalk between Tumor Cells and Hematopoietic Stem Cells Reveals a Myeloid Differentiation Pattern Signature Contributing to Metastasis

Inhibiting Matrix Metalloproteinases Hinders Acute Myeloid Leukaemia and Prevents Healthy Stem Cell Loss

Characteristics and Outcomes of Patients with Lymphoma Who Developed Therapy-Related Acute Myeloid Leukemia or Myelodysplastic Syndrome - a Retrospective Analysis of the Polish Adult Leukemia Group

AVM0703, a New Treatment Option for Lymphoma Patients

Niveau, a Phase 3 Study for Pts with B- or T-Cell Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivo lumab in Combination with G e mcitabine, Ox a liplatin (GemOx), Plus Rit u ximab (R) in Case of B-Cell Lymphoma

Leukemia Cutis As an Early Presentation or Relapsing Manifestation of Chronic Lymphocytic Leukemia

Insulin-like Growth Factor-1-Induced Epithelial-Mesenchymal Transition Promotes Multiple Myeloma Progression

Metastatic Lymphoepithelioma-like Carcinoma Treated with PD1-Antibody:Is Epstein-Barr Virus Eradication the Main Mechanism in 2 Refractory Cases in Children?

ANTI-PD-1 Treatment in a Family with Constitutional Mismatch Repair Deficiency Syndrome with Multiple Cancers from Turkey. Is Cancer Immunoprevention with Checkpoint Inhibitors HAS a Role in CASES with Homozygous Mutationis

Analysis of Outcomes of Younger (≤ 55 Years) Compared with Older (> 55 Years) Patients with Chronic Lymphocytic Leukaemia (CLL) in Seven Studies Conducted By the German CLL Study Group (GCLLSG)

FBXO11 Is a Candidate Tumor Suppressor in the Transformation of MDS to Secondary AML

Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase Inhibition

Oral Fludarabine and Intravenous Rituximab (FR) for Chronic Lymphocytic Leukemia (CLL): Long Term Outcomes and Secondary Malignancies in 673 Patients Treated in British Columbia (BC)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only